Last reviewed · How we verify
Quadrivalent influenza vaccine, high-dose
Quadrivalent influenza vaccine, high-dose is a vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 3 development for Prevention of influenza in adults aged 65 years and older, Prevention of influenza in immunocompromised populations.
A high-dose quadrivalent influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus.
A high-dose quadrivalent influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus. Used for Prevention of influenza in adults aged 65 years and older, Prevention of influenza in immunocompromised populations.
At a glance
| Generic name | Quadrivalent influenza vaccine, high-dose |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated influenza virus antigens from four different strains (two influenza A subtypes and two influenza B lineages) at higher antigen doses than standard-dose formulations. This enhanced antigen content is designed to elicit a stronger and more durable immune response, particularly in older adults and immunocompromised populations who may have diminished responses to standard-dose vaccines.
Approved indications
- Prevention of influenza in adults aged 65 years and older
- Prevention of influenza in immunocompromised populations
Common side effects
- Injection site pain
- Injection site erythema
- Injection site swelling
- Myalgia
- Fatigue
- Headache
Key clinical trials
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza (PHASE1)
- A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer (PHASE1)
- Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older (PHASE1)
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
- A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age. (PHASE1)
- Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Quadrivalent influenza vaccine, high-dose CI brief — competitive landscape report
- Quadrivalent influenza vaccine, high-dose updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about Quadrivalent influenza vaccine, high-dose
What is Quadrivalent influenza vaccine, high-dose?
How does Quadrivalent influenza vaccine, high-dose work?
What is Quadrivalent influenza vaccine, high-dose used for?
Who makes Quadrivalent influenza vaccine, high-dose?
What drug class is Quadrivalent influenza vaccine, high-dose in?
What development phase is Quadrivalent influenza vaccine, high-dose in?
What are the side effects of Quadrivalent influenza vaccine, high-dose?
Related
- Drug class: All vaccine drugs
- Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of influenza in adults aged 65 years and older
- Indication: Drugs for Prevention of influenza in immunocompromised populations
- Compare: Quadrivalent influenza vaccine, high-dose vs similar drugs
- Pricing: Quadrivalent influenza vaccine, high-dose cost, discount & access